Details of the Drug

General Information of Drug (ID: DMZABYH)

Drug Name
GEN3013
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [1]
Follicular lymphoma 2A80 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D9OMQ3
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Not Available [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
2 DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.